Group: Randox
Catalog excerpts
Cardiac Risk Prediction Array Comprehensive genetic risk assessment for CHD
Open the catalog to page 1Cardiac Risk Prediction Array Simultaneous genotyping of 19 SNPs for a reliable CHD risk assessment Introduction Coronary Heart Disease (CHD) is the leading cause of death in the developed world and its prevention is a core activity in general practice worldwide. For example, clinical guidelines from the Joint Cardiac Societies and NICE in the UK recommend that patients at greater than 20% risk of CHD in the next ten years should be classified as high risk and considered for intensive lifestyle intervention and lipid lowering therapy,1 primarily the prescription of statins. Current CHD risk...
Open the catalog to page 2Response to statin treatment A fur ther impor tant SNP which can predict response to par ticular statin therapies has been included in the array. Individuals who are homozygous (frequency =0.13) for the risk allele are 17 times more likely to suffer from statin-induced myopathy when treated with high doses of simvastatin.8 Identifying patients with a higher risk of suffering statin-induced myopathy would allow clinicians to make more informed decisions when prescribing lipid lowering therapies. Cardiac Risk Prediction Array Protocol Step 1 Extraction Genomic DNA extracted from blood/saliva...
Open the catalog to page 3Evidence Investigator Multiplexing...proven, perfected, evolved The Evidence Investigator is a semi-automated, benchtop biochip analyser which offers complete patient profiling. Save time and costs Multiplexing reduces time, labour and reagents associated with multiple individual tests Increase throughput For greater laboratory efficiency Consolidation Of immunoassays and molecular diagnostics, improving laboratory efficiency Result traceability Chain of custody features and bar coded reagents No hidden costs Package includes imaging module, PC and imaging software, thermoshaker, biochip...
Open the catalog to page 4All Randox Laboratories catalogs and technical brochures
-
Acusera New Controls
8 Pages
-
Acusera 24.7
24 Pages
-
Acusera Third Party Controls
108 Pages
-
Acusera SMART Controls
12 Pages
-
Company Overview
40 Pages
-
LT735 Vivalytic Overview
32 Pages
-
Reagents Brochure
64 Pages
-
sdLDL-C
8 Pages
-
RX SERIES ANALYSER OVERVIEW
24 Pages
-
RX modena
20 Pages
-
RX misano
20 Pages
-
RX Daytona Plus
20 Pages
-
Rx Imola
20 Pages
-
RX Monaco
20 Pages
-
2024 Product List
64 Pages
-
LT107 Evidence Investigator
32 Pages
-
VeraSTAT-V
16 Pages
-
LT033 RIQAS Explained
64 Pages
-
VERASTAT
16 Pages
-
Endocrine Array
4 Pages
-
Cerebral Arrays
4 Pages
-
Thyroid Arrays
4 Pages
-
Respiratory Multiplex Array
8 Pages
-
LT253 Molecular Diagnostics
20 Pages
-
LT367 FH Array Brochure
4 Pages
-
The role of EQA in QC
8 Pages
-
Basic QC Stastics
8 Pages
-
Commutability Guide
4 Pages
-
How to measure uncertainty
8 Pages
-
ISO 15189 Educational Guide
8 Pages
-
Troubleshooting QC Errors
8 Pages
-
Qnostics
52 Pages
-
Adiponectin LT519
28 Pages
-
Specific Proteins
40 Pages
-
Linearity sets
12 Pages
-
Antioxidants
16 Pages
-
Cardiology & Lipid Testing
28 Pages
-
Diabetes Portfolio
28 Pages
-
Total Bile Acids
4 Pages
-
VIVALYTIC
30 Pages
-
RANDOX DISCOVERY
36 Pages
-
HbA1c
2 Pages
-
Preparing QC
1 Pages
-
Point of Care Testing
12 Pages
-
LT394 Using QC Multirules
1 Pages
-
Guide to running QC
1 Pages
-
Tumour Marker Arrays
4 Pages
-
Which QC is the Right QC
8 Pages
-
How often is right for QC
6 Pages
-
LT241 Metabolic Array MAY15
8 Pages
-
KRAS / BRAF / PIK3CA Array*
4 Pages
-
Custom Arrays for Biochip
12 Pages
-
LT169 Cardiac Array
4 Pages
Archived catalogs
-
ACUSERA
108 Pages
-
Evidence Evolution
28 Pages
-
Evidence
16 Pages
-
Metabolic Syndrome Arrays
8 Pages
-
STI Multiplex Array
8 Pages
-
Molecular Testing
16 Pages
-
Evidence Investigator
20 Pages
-
Fertility Array
4 Pages
-
Rx Daytona
16 Pages
-
Evidence Investigator
16 Pages
-
Evidence
16 Pages